The Effect Of Chemotherapy Or Hematopoietic Stem Cell Transplantation Combined With Cytokine-induced Killer Cell As Treatment For Hematologic Malignancy

ObjectiveObserve the effect of chemotherapy or hemopoietic stem cell transplantation combinedwith cytokine-induced killer (CIK) cell as treatment for hematologic malignancy.MethodCollect44patients of hematologic malignancy received different treatment in ourdepartment from January2006to June2010, among which there were21cases hadreceived treatment combined with CIK cell, while other23cases had received treatmentwithout CIK cell. Calculate the life cycle with the time diagnosed of hematologicmalignancy as the origin and the time of death as the endpoint and the time to relapsewith the end of treatment as the origin and the end of follow-up as the endpoint. Thenthe survival and relapse rates were reviewed retrospectively. We used the SPSS18.0andKaplan-meier to evaluate the effect of CIK.ResultBy the end of follow-up, there were6cases relapsed(23.81%) and5cases died in21cases received CIK cell therapy. While in23cases received no CIK cell therapy, therewere13cases relapsed(56.52%) and17cases died(P<0.05). The survival rate ofreceiving treatment for6,12and36months were93.1%，86.9%and86.9%in treatmentgroup, while82.4%,64.8%and39.5%in controlled group, and the survival rate oftreatment group is higher than controlled group in all time periods(P<0.05).The effect oftreatment combined with CIK cell was better for acute myeloid leukemia (AML) and the rate of relapse was also lower (P=0.03). While for acute lymphocytic leukemia(ALL) and multiple myeloma (MM), there was no significant difference by therapeuticeffect or the rate of relapse (P=0.51/P=0.54).ConclusionChemotherapy or hemopoietic stem cell transplantation combined withcytokine-induced killer cell could improve the long time survival and reduce therecurrence rate of patients with hematologic malignancy, for which it could be used asan important clinical therapy to improve the treatment effect of the hematologicmalignancy and then prolong the survival time of patients suffered with hematologicmalignancy.